RxDoctor Payments DataLook up a doctor →

Sharon Sha, MD

Behavioral Neurology & Neuropsychiatry · Stanford, CANPI 1225299027

Payments from drug & device makers

$6,403,752in general payments, 2019–2025

Across 280 payments — averaging $22,871 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$2.3M
  • Eisai Inc.$1M
  • Novartis$841K
  • Eli Lilly$779K
  • Genentech, Inc.$682K
  • Janssen Research & Development, LLC$566K
  • plus $190K from 6 others
$17,057in research payments, 2019–2025

Across 4 payments — averaging $4264.14 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Biogen$15K
  • Eli Lilly$2K

General payments by program year

19
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Biogen27$2,333,684
Eisai Inc.94$1,012,455
Novartis4$840,678
Eli Lilly18$779,344
Genentech, Inc.69$682,255
Janssen Research & Development, LLC47$565,673
UCB SA4$88,855
Merck11$64,155
Acadia Pharmaceuticals Inc2$30,122
E.r. Squibb & Sons, L.L.C.2$5,343
Genentech USA, Inc.1$1,020
Medtronic1$169

How this compares

Too few behavioral neurology & neuropsychiatry providers in Californiato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$39,565
Medicare patients
182
Services billed
235

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other behavioral neurology & neuropsychiatry in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →